Selzentry Dosage

Generic name: maraviroc
Dosage form: tablet, film coated

This dosage information does not include all the information needed to use Selzentry safely and effectively. See full prescribing information for Selzentry.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Dose Recommendations for Patients With Normal Renal Function

The recommended dose of SELZENTRY differs based on concomitant medications due to drug interactions (see Table 1). SELZENTRY can be taken with or without food. SELZENTRY must be given in combination with other antiretroviral medications.

Table 1 gives the recommended dose adjustments [see Drug Interactions (7.1)].

Table 1. Recommended Dosing Regimen

Concomitant Medications

Dose of SELZENTRY

Potent CYP3A inhibitors (with or without a potent CYP3A inducer) including:

protease inhibitors (except tipranavir/ritonavir)
delavirdine
ketoconazole, itraconazole, clarithromycin
other potent CYP3A inhibitors (e.g., nefazodone, telithromycin)

150 mg twice daily

Other concomitant medications, including tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, and enfuvirtide

300 mg twice daily

Potent CYP3A inducers (without a potent CYP3A inhibitor) including:

efavirenz
rifampin
etravirine
carbamazepine, phenobarbital, and phenytoin

600 mg twice daily

Dose Recommendations for Patients With Renal Impairment

Table 2 provides dosing recommendations for patients based on renal function and concomitant medications.

Table 2. Recommended Dosing Regimens Based on Renal Function

Concomitant Medicationsa

Dose of SELZENTRY Based on Renal Function

Normal

(CrCl >80 mL/min)

Mild

(CrCl >50 and ≤80 mL/min)

Moderate

(CrCl ≥30 and ≤50 mL/min)

Severe

(CrCl <30 mL/min)

End-Stage Renal Disease

On Regular Hemodialysis

Potent CYP3A inhibitors (with or without a CYP3A inducer)a

150 mg twice daily

150 mg twice daily

150 mg twice daily

NR

NR

Other concomitant medicationsa

300 mg twice daily

300 mg twice daily

300 mg twice daily

300 mg twice dailyb

300 mg twice dailyb

Potent CYP3A Inducers (without a potent CYP3A inhibitor)a

600 mg twice daily

600 mg twice daily

600 mg twice daily

NR

NR

NR = Not recommended.

aSee Table 1 for the list of concomitant medications.

bThe dose of SELZENTRY should be reduced to 150 mg twice daily if there are any symptoms of postural hypotension [see Warnings and Precautions (5.3)].

Hide
(web5)